Evidence map›Paper›PMID 40100605›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Protocols for Studying Graft-Versus-Leukemia Immunity in Mice.

Catharina Lucas Sena, Isadora Oliveira Gondim, Elisabete Pisnitchenko Ferreira, Sabrina Berger da Silva, Maísa Mota Antunes, Marina Gomes Miranda Castor, Barbara Maximino Rezende

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catharina Lucas SenaEscola de Enfermagem, Departamento de Enfermagem Básica/Programa de Pós-graduação em Patologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Isadora Oliveira GondimEscola de Enfermagem, Departamento de Enfermagem Básica/Programa de Pós-graduação em Patologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Elisabete Pisnitchenko FerreiraEscola de Enfermagem, Departamento de Enfermagem Básica/Programa de Pós-graduação em Patologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Sabrina Berger da SilvaEscola de Enfermagem, Departamento de Enfermagem Básica/Programa de Pós-graduação em Patologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Maísa Mota AntunesCenter for Gastrointestinal Biology, Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Marina Gomes Miranda CastorPrograma de Pós-graduação em Ciências Biológicas: Fisiologia e Farmacologia, Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Barbara Maximino RezendeEscola de Enfermagem, Departamento de Enfermagem Básica/Programa de Pós-graduação em Patologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. barbaramaximino@ufmg.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For patients with leukemia and other hematological malignancies, allogeneic hematopoietic stem cell transplantation (allo-SCT) represents a primary treatment option. This therapy involves the transplantation of healthy stem cells from a compatible donor into a preconditioned recipient. These transplanted cells then recognize and attack the remaining leukemia cells or other malignant cells in the recipient, a process named graft-versus-leukemia (GVL) immunity. This immunological response contributes to the therapeutic effect of the transplant, reducing the risk of disease relapse or progression. However, it can also lead to graft-versus-host disease (GVHD), the main complication related to allo-SCT. Therefore, effective treatment requires a balance between GVL immunity and GVHD. This chapter describes protocols for studying GVL immunity in allogeneic and humanized (xenogeneic) mouse models, including the challenges and strategies encountered in the induction of GVL immunity in such models.

Indexed as

Graft vs Leukemia EffectHematopoietic Stem Cell TransplantationLeukemiaAnimalsDisease Models, AnimalGraft vs Host DiseaseHumansMiceTransplantation, HomologousAllogeneic graft-versus-host-diseaseBioluminescenceChronic myeloid leukemiaFlow cytometryGraft-versus-host-diseaseGraft-versus-leukemiaK562 cellsMastocytomaP815 cellsXenogeneic graft-versus-host-disease

Identifiers

PMID40100605

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.